Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients

Bone Marrow Transplantation volume 36, pages 499–501 (2005)Cite this article

Summary:

Leukoreduction of blood components has been considered a safe alternative to screening donors for CMV. The objective of this study is to analyze the effectiveness of bedside leukoreduction in preventing CMV transmission. We retrospectively studied 72 transplant recipients and donors who were CMV-seronegative pairs. All patients were transfused with CMV-unscreened cellular blood products leukoreduced at the bedside using leukoreduction filters. Quality control measures performed monthly in our leukoreduced blood components consistently demonstrated that at least 95% of the units sampled meet the leukoreduction criterion established by the American Association of Blood Banks standards. The CMV status of the recipients and donors was determined before transplantation by the latex agglutination assay. Recipients were observed for at least 100 days after transplantation. CMV cultures of urine, buffy coat, bone marrow, and bronchial washings were done weekly when indicated. CMV antigenemia testing was performed twice weekly: 11 transplant recipients seroconverted after transplantation. One patient was positive for CMV antigenemia 4 months after transplantation, but did not have CMV infection. Two of 61 patients who were not seroconverted were CMV antigenemia positive and did not have CMV infection: leukoreduction of cellular blood products is an efficient method of preventing CMV infection.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Delgado R, Lumbreras C, Alba C et al. Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in live transplant recipients. J Clin Microbiol 1992; 30: 1876–1878.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Reusser P, Riddell SR, Meyers JD, Greenberg PD . Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373–1380.

    CAS  Google Scholar 

  3. Ettinger NA . Pulmonary considerations of organ transplantation. Part 2. Am Rev Respir Dis 1991; 144: 213–223.

    Article  CAS  Google Scholar 

  4. Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419–1425.

    Article  CAS  Google Scholar 

  5. Siad G, Patel R . New strategies for prevention and therapy of cytomegalovirus infection and disease solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83–121.

    Article  Google Scholar 

  6. Larsson S, Soderberg-Naucler C, Wang F-Z et al. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and seronegative healthy blood donors over time. Transfusion 1998; 38: 271–278.

    Article  CAS  Google Scholar 

  7. Zhang LJ, Hanff P, Rutherford C et al. Detection of human cytomegalovirus DNA, RNA and antibody in normal donor blood. J Infect Dis 1995; 171: 1002–1006.

    Article  CAS  Google Scholar 

  8. Narvios AB, Przepiorka D, Tarrand J et al. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 1998; 22: 575–577.

    Article  CAS  Google Scholar 

  9. Narvios A, Lichtiger B . Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica 2001; 86: 749–752.

    CAS  PubMed  Google Scholar 

  10. Narvios A, Pena E, Han XY, Lichtiger B . Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood 2002; 99: 390–391.

    Article  CAS  Google Scholar 

  11. Vij R, DiPersio J, Venkatraman P et al. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood 2003; 101: 2067–2069.

    Article  CAS  Google Scholar 

  12. Meyers JD . Prevention of cytomegalovirus infection after marrow transplantation. Rev Infect Dis 1989; 11 (Suppl. 7): S1691–S1705.

    Article  Google Scholar 

  13. Neiman PE, Reeves W, Ray G et al. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts. J Infect Dis 1977; 136: 754–767.

    Article  CAS  Google Scholar 

  14. Boland GJ, Vlieger AM, Ververs C, de-Gast GC . Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin Exp Immunol 1992; 88: 506–511.

    Article  CAS  Google Scholar 

  15. Gorlin JB (ed). Standards for Blood Banks and Transfusion Services. 21st edn, American Association of Blood Banks: Bethesda, MA, 2002, p 29.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    A B Narvios & B Lichtiger

  2. Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M de Lima

  3. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    H Shah

Authors
  1. A B Narvios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M de Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Lichtiger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A B Narvios.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Narvios, A., de Lima, M., Shah, H. et al. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 36, 499–501 (2005). https://doi.org/10.1038/sj.bmt.1705090

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705090

Keywords

This article is cited by

Search

Advanced search

Quick links